Description: Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy, toxicology studies, and orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and natural killer cell-mediated anti-cancer action. The company was incorporated in 2020 and is based in London, the United Kingdom.
Home Page: www.roquefortplc.com
85 Great Portland Street
London,
W1W 7LT
United Kingdom
Phone:
44 20 3918 8633
Officers
| Name | Title |
|---|---|
| Mr. Stephen Paul West B.Com, CA | Executive Chairman |
| Mr. Trevor Ajanthan Reginald | CEO & Executive Director |
| Dr. Emma Morris | Head of Pre-Clinical Research |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0786 |
| Price-to-Sales TTM: | 29.9907 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 10 |